Metformin on Albumin
Excretion in Patients With
Newly Diagnosed Type 2
Diabetes
A Rondomized Controlled Trial
Qingrong Pan, MD, Yuan Xu, MD, Ning Yang, MD, Xia Gao, MD, Jia Liu, MD,
Wenying Yang, MD, and Guang Wang, MD
Pendahuluan
Multicenter, RCT
Dilakukan di 11 RS di China
Dilakukan informed consent
Disetujui oleh komite etik di setiap RS
Partisipan didiagnosis DM tipe 2, 12 bulan sebelum studi dilakukan
berdasarkan kriteria WHO 1999
Inklusi Ekslusi
Usia 30 – 70 tahun Riwayat penyakit ginjal dengan creatinine ≥1,5 mg/dL
Tidak konsumsi OHO atau baru minum 1 bulan Riwayat penyakit jantung (UAP, Infark) 6 bulan terakhir
dan dihentikan selama 3 bulan sebelum studi
Randomisasi
Metode Penggunaan
Two tailed paired t test atau Wilcoxon Perubahan parameter dari nilai baseline
signed-rank test
Spearman correlation Analisa korelasi perubahan ACR dengan
parameter lainnya
Hasil Penelitian
1099 screening
333 ekslusi
4 mengundurkan diri
762 dirandomisasi
Minggu 24 Minggu 24
n(340) n(345)
Minggu 48 Minggu 48
n(315) n(329)
Analisis Baseline
Penurunan ACR terhadap baseline pada grup acarbose lebih besar pada grup
acarbose dibanding metformin pada minggu ke 48
Uji Korelasi
Acarbose memiliki efek lebih baik dibandingkan metformin terhadap ACR pada
minggu 48, dimungkinkan karena efek penurunan TG yang hanya dimiliki acarbose
Pada penelitian lain TG tinggi dilaporkan berhubungan dengan penurunan fungsi ginjal
dan albuminuria pada pasien DM tipe 2 24-25
Studi lain menunjukkan asam lemak yang berasal dari TG mampu menembus glomerulus
dan menimbulkan kerusakan glomerular dan tubular 26
Pada studi FIELD (Fenofibrate Intervention and Event Lowering in Diabetes) dan DAIS
(Diabetes Atherosclerosis Intervention Study) menunjukkan penurunan TG dan eksresi
albumin oleh fenofibrat 27-28
Partisipan studi MARCH dengan diet karbohidrat (67%) lebih tinggi dari guideline
(45% - 65%) 14
Penggunaan acarbose kemungkinan menunjukkan efek protektif lebih baik pada populasi
dengan diet karbohidrat tinggi
Keterbatasan Penelitian
Metformin dan acarbose menrurunkan ACR urin, frekuensi ACR meningkat dan
MetS pada orang China yang baru terdiagnosis diabetes tipe 2 tanpa adanya
perbuahan eGFR
Monoterapi acarbose menunjukkan penurunan ACR urin lebih baik
dibandingkan metformin setelah pengobatan 48 minggu
Telaah Kritis 29
1. de Zeeuw D. Albuminuria: a target for treatment of type 2 diabetic nephropathy. Semin Nephrol. 2007;27:172–181.
2. Bakris GL, Molitch M. Microalbuminuria as a risk predictor in diabetes: the continuing saga. Diabetes Care. 2014;37:867–875.
3. Parving HH, Persson F, Rossing P. Microalbuminuria: a parameter that has changed diabetes care. Diabetes Res Clin
Pract.2015;107:1–8.
4. Meigs JB, D’Agostino RS, Nathan DM, et al. Longitudinal association of glycemia and microalbuminuria: the Framingham
Offspring Study. Diabetes Care. 2002;25:977–983.
5. Hsu CC, Chang HY, Huang MC, et al. Association between insulin resistance and development of microalbuminuria in type 2
diabetes: a prospective cohort study. Diabetes Care. 2011;34:982–987.
6. Viazzi F, Pontremoli R. Blood pressure, albuminuria and renal dysfunction: the ’chicken or egg’ dilemma. Nephrol Dial
Transplant. 2014;29:1453–1455.
7. Prasad GV. Metabolic syndrome and chronic kidney disease: Current status and future directions. World J Nephrol.
2014;3:210–219.
8. DCCT/EDIC research group. Effect of intensive diabetes treatment on albuminuria in type 1 diabetes: long-term follow-up of
the Diabetes Control and Complications Trial and Epidemiology of Diabetes Interventions and Complications study. Lancet
Diabetes Endocrinol. 2014;2:793–800.
9. D’Elia L, Rossi G, Schiano DCM, et al. Meta-Analysis of the Effect of Dietary Sodium Restriction with or without Concomitant
Renin-Angiotensin-Aldosterone System-Inhibiting Treatment on Albuminuria. Clin J Am Soc Nephrol. 2015;10:1542–1552.
Daftar Pustaka
10. Haller H, Ito S, Izzo JJ, et al. Olmesartan for the delay or prevention of microalbuminuria in type 2
diabetes. N Engl J Med. 2011;364:907–917.
11. American Diabetes Association. Standards of medical care in diabetes–2014. Diabetes Care.
2014;37(Suppl 1):S14–S80.
12. Ryden L, Grant PJ, Anker SD, et al. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular
diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and
cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the
European Association for the Study of Diabetes (EASD). Eur Heart J. 2013;34:3035–3087.
13. Wang G, Liu J, Yang N, et al. MARCH2: comparative assessment of therapeutic effects of acarbose and
metformin in newly diagnosed type 2 diabetes patients. PLoS One. 2014;9:e105698.
14. Yang W, Liu J, Shan Z, et al. Acarbose compared with metformin as initial therapy in patients with newly
diagnosed type 2 diabetes: an open-label, non-inferiority randomised trial. Lancet Diabetes Endocrinol.
2014;2:46–55.
15. UK Prospective Diabetes Study (UKPDS). X. Urinary albumin excretion over 3 years in diet-treated type
2, (non-insulin-dependent) diabetic patients, and association with hypertension, hyperglycaemia and
hypertriglyceridaemia. Diabetologia. 1993;36:1021–1029.
16. Pistrosch F, Herbrig K, Kindel B, et al. Rosiglitazone improves glomerular hyperfiltration, renal
endothelial dysfunction, andmicroalbuminuria of incipient diabetic nephropathy in patients.Diabetes.
2005;54:2206–2211.
17. Diabetes Prevention Program research group. Changes in albumin excretion in the diabetes
prevention program. Diabetes Care. 2009;32:720–725.
18. Ma YC, Zuo L, Chen JH, et al. Modified glomerular filtration rate estimating equation for Chinese
patients with chronic kidney disease. J Am Soc Nephrol. 2006;17:2937–2944.
19. Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic
syndrome: an American Heart Association/ National Heart, Lung, and Blood Institute Scientific
Statement. Circulation. 2005;112:2735–2752.
20. Amador-Licona N, Guizar-Mendoza J, Vargas E, et al. The shortterm effect of a switch from
glibenclamide to metformin on blood pressure and microalbuminuria in patients with type 2
diabetes mellitus. Arch Med Res. 2000;31:571–575.
21. Lachin JM, Viberti G, Zinman B, et al. Renal function in type 2 diabetes with rosiglitazone,
metformin, and glyburide monotherapy. Clin J Am Soc Nephrol. 2011;6:1032–1040.
22. Schernthaner G, Matthews DR, Charbonnel B, et al. Efficacy and safety of pioglitazone versus
metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial. J Clin
Endocrinol Metab. 2004;89:6068–6076.
23. Imano E, Kanda T, Nakatani Y, et al. Effect of troglitazone onmicroalbuminuria in patients with
incipient diabetic nephropathy. Diabetes Care. 1998;21:2135–2139.
24. Kim DM, Ahn CW, Park JS, et al. An implication of hypertriglyceridemia in the progression
of diabetic nephropathy in metabolically obese, normal weight patients with type 2 diabetes
mellitus in Korea. Diabetes Res Clin Pract. 2004;66(Suppl 1):S169–S172.
25. Sun K, Lin D, Li F, et al. Discordant associations of lipid parameters with albuminuria and
chronic kidney disease: a population-based study. Lipids Health Dis. 2015;14:152.
26. Weinberg JM. Lipotoxicity. Kidney Int. 2006;70:1560–1566.
27. Keech A, Simes RJ, Barter P, et al. Effects of long-term fenofibrate therapy on
cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study):
randomised controlled trial. Lancet. 2005;366:1849–1861.
28. Ansquer JC, Foucher C, Rattier S, et al. Fenofibrate reduces progression to
microalbuminuria over 3 years in a placebocontrolled study in type 2 diabetes: results from
the Diabetes Atherosclerosis Intervention Study (DAIS). Am J Kidney Dis. 2005;45:485–493.
29. BMJ Clinical Evidence(2012), Appraising 2-armed randomized controlled trials,
URL:http://clinicalevidence.bmj.com/x/mmo/ce/en-gb/checklist-2-armed-rct_default.ppt:
Date Accessed. 11-10-2017
TERIMA KASIH